Clicky

Corvus Pharmaceuticals, Inc.(CRVS)

Description: Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that plan to initiate a Phase 1/1b clinical trial for adenosine, an immune checkpoint. The company also develops a product candidate, an anti-CD73 monoclonal antibody that inhibits the production of adenosine. Corvus Pharmaceuticals, Inc. was founded in 2014 and is based in Burlingame, California.


Keywords: Biotechnology Biopharmaceutical Life Sciences Immunology Immune System Cancer Immunotherapy Monoclonal Antibody Cancer Cell Adenosine Immune Checkpoint Oncology Therapies Cd73 Attack Cancer

Home Page: www.corvuspharma.com

CRVS Technical Analysis

863 Mitten Road
Burlingame, CA 94010
United States
Phone: 650 900 4520


Officers

Name Title
Dr. Richard A. Miller M.D. Co-Founder, Pres, CEO & Chairman
Dr. Peter A. Thompson FACP, M.D. Co-Founder & Independent Director
Mr. Leiv Lea Chief Financial Officer
Dr. William Benton Jones Ph.D. Sr. VP of Pharmaceutical Devel.
Dr. Erik J. Verner Ph.D. Co-Founder
Dr. James T. Rosenbaum M.D. Sr. VP of Research
Mr. Alan C. Mendelson Esq. Sec.

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.576
Price-to-Sales TTM: 0
IPO Date: 2016-03-23
Fiscal Year End: December
Full Time Employees: 28
Back to stocks